Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Placebo-controlled, Double-blind Clinical Study to Evaluate Efficacy and Safety of LAD603 in Adult Subjects With Severe to Very Severe Alopecia Areata

NCT07311564 is registered in ClinicalTrials.gov with Almirall, S.A. as lead sponsor.

NCT NCT07311564
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07311564 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Placebo-controlled, Double-blind Clinical Study to Evaluate Efficacy and Safety of LAD603 in Adult Subjects With Severe to Very Severe Alopecia Areata
Lead sponsor
Almirall, S.A.
Phase
Phase 2
Overall status
Recruiting
Start date
December 17, 2025
Completion date
November 21, 2027
Enrollment
136 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alopecia areata